Shenzhen RuiJin Pharmaceutical Co.,Ltd 86-188-06592208 Gavin@hgh-steroid.com
Letrozole / Femara 112809-51-5 Anti Estrogen Steroids For Breast Cancer

Letrozole / Femara 112809-51-5 Anti Estrogen Steroids For Breast Cancer

  • High Light

    112809-51-5

    ,

    Letrozole

  • Product name
    Letrozole
  • Other Name
    Femara
  • CAS register number
    112809-51-5
  • Molecular formula
    C17H11N5
  • Molecular weight
    285.3
  • Appearance
    White Powder
  • Usage
    Used As API In Treatment Of Breast Disease.
  • Type
    Anti Estrogen Steroids
  • Place of Origin
    China
  • Brand Name
    RuiiJin
  • Certification
    ISO9001
  • Model Number
    112809-51-5
  • Minimum Order Quantity
    10g
  • Price
    Negotiable
  • Packaging Details
    Disguised package or according to your requirement
  • Delivery Time
    Within 24hours after payment
  • Payment Terms
    Western union and moneygram,Bank transfer,Bitcoin, T/T
  • Supply Ability
    3000t/month

Letrozole / Femara 112809-51-5 Anti Estrogen Steroids For Breast Cancer

Letrozole / Femara 112809-51-5 Anti Estrogen Steroids For Breast Cancer

 

→→Anti-Estrogens Series Product :

 

Anti-estrogen Series

Tamoxifen Citrate

CAS No.: 563.64

Clomifene Citrate

CAS No.: 50-41-9

Toremifene Citrate

CAS No.: 89778-27-8

Exemestane

CAS No.: 107868-30-4

Anastrozole

CAS No.: 120511-73-1

Letrozole

CAS No.: 112809-51-5

Fulvestrant

CAS No.: 129453-61-8

 

→→Letrozole Quick Detail:

 

Letrozole can sometimes also be used:

 

  • to prevent breast cancer if you are high risk and have been through the menopause
  • to treat breast cancer in men and younger women
  • as a fertility treatment if you have polycystic ovary syndrome

 

Product name Letrozole
Other name Femara
CAS register number 112809-51-5
Molecular formula C17H11N5
Molecular weight 285.3
Molecular structure Anti Estrogen Bodybuilding Steroids Letrozole Femara White Powder CAS 112809-51-5
Assay 99%
Appearance White Powder
Minimum order quantity 10g
Package: Exquisite and can according to customers’ requirement
Shipping leading time Within 24 hours after receiving the payment
Payment options Western Union, MoneyGram, bank transfer, Bitcoin

 

 

→→Letrozole Dosage For Breat Cancer: 

 

For use as first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Letrozoleis also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy: 2.5 mg tablet orally administered once a day without regard to meals.

In patients with advanced disease, Letrozole therapy should continue until tumor progression is evident.

 

For use as extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy: 2.5 mg tablet orally administered once a day without regard to meals.

The optimal duration of treatment with Letrozole is not known. Treatment should be discontinued if there is a tumor relapse

 

 

 

 

→→Letrozole Recipes:

 

200ml @ 5 mg/ml
1 gram of Letrozole powder
1 beaker suitable for holding the volume of liquids
19.9 ml of PEG 300
179.1 ml of 190 Proof Grain Alcohol

 

 

 

 

→→Letrozole Usage :


Letrozole in postmenopausal patients with advanced breast cancer whose Estrogen receptor and / or progesterone receptor positive or receptor status unknown
Letrozole(letrozole) is a type II (non-steroidal) third generation aromatase inhibitor. Clinically it is used to treat postmenopausal women with either estrogen receptor positive or estrogen receptor unknown breast cancer.

 

  1. Letrozole is a powerful Aromatase Inhibitor that was developed to fight breast cancer.
  2. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia.
  3. It will also raise testosterone levels because of the lowered estrogen in the body.
  4. Femara(generic name is letrozole) is a new drug developed for the treatment of advanced breast cancer in women.
  5. Letrozoleis the second in a new class of third-generation selective oral aromatase inhibitors.
  6. It acts by blocking the enzyme aromatase, subsequently blocking the production of estrogen.